Samlyn Capital, LLC Bicycle Therapeutics PLC Transaction History

Samlyn Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$20.37 - $32.9 $6.24 Million - $10.1 Million	-306,197 Reduced 23.66%	987,888 $29.2 Million
Q3 2022 Nov 14, 2022	BUY	$17.49 - $28.44 $4.44 Million - $7.22 Million	253,846 Added 24.4%	1,294,085 $30.1 Million
Q2 2022 Aug 15, 2022	BUY	$12.95 - $46.99 $7.95 Million - $28.8 Million	613,696 Added 143.88%	1,040,239 $17.5 Million
Q1 2022 May 16, 2022	BUY	$40.12 - $59.5 $4.71 Million - $6.99 Million	117,428 Added 37.99%	426,543 $18.7 Million
Q4 2021 Feb 14, 2022	SELL	$41.7 - $61.14 $6.08 Million - $8.91 Million	-145,766 Reduced 32.04%	309,115 $18.8 Million
Q3 2021 Nov 15, 2021	BUY	$27.95 - $44.24 $324,639 - $513,847	11,615 Added 2.62%	454,881 $18.9 Million
Q2 2021 Aug 16, 2021	BUY	$27.0 - $32.28 $149,526 - $178,766	5,538 Added 1.27%	443,266 $13.5 Million
Q1 2021 May 17, 2021	SELL	$19.12 - $30.25 $5,850 - $9,256	-306 Reduced 0.07%	437,728 $13.1 Million
Q4 2020 Feb 16, 2021	BUY	$17.95 - $21.36 $350,958 - $417,630	19,552 Added 4.67%	438,034 $7.86 Million
Q3 2020 Nov 16, 2020	BUY	$15.3 - $20.8 $6.4 Million - $8.7 Million	418,482 New	418,482 $7.97 Million

111

40.8M

39.6K

24.6K

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $433M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

Get notified when there are updates to the investment portfolio of Samlyn Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samlyn Capital, LLC with notifications on news.